Health Bulletin 13/September/2025

Here are the top health stories of the day:

NEET PG 2025: Supreme Court postpones hearing by 2 weeks

The Supreme Court of India has postponed the hearing of the National Eligibility-Entrance Test Postgraduate (NEET-PG) 2025 examination-related case hearing.

The top court bench was supposed to take up all the pending matters related to NEET PG transparency today, but the Court has now adjourned the matter for two weeks.

As per the Supreme Court’s official website, the case has been listed for further hearing on 23.09.2025.

Medical Dialogues had earlier reported that a group of NEET-PG 2025 aspirants filed a plea before the Supreme Court challenging the “corrective notice” issued by the National Board of Examinations in Medical Sciences (NBEMS) on August 21.

For more details, check out the full story on the link below:

Supreme Court Delays NEET PG Transparency Case Hearing by Two Weeks

Delhi High Court seeks UPSC reply on reservation for blind, low vision candidates in Combined Medical Services exam

The Delhi High Court recently sought to know the Union Public Service Commission’s (UPSC) stance on a plea seeking one percent reservation for candidates with blindness and low vision in the Combined Medical Services Examination (CMSE).

While considering the matter, the HC bench comprising Chief Justice Devendra Kumar Upadhyaya and Justice Tushar Rao Degela issued notices to the UPSC, the Department of Personnel and Training (DoPT), the Union Ministry of Health and Family Welfare, and the Department of Empowerment of Persons with Disabilities (DEPwD).

For more details, check out the full story on the link below:

Delhi High Court Seeks UPSC Reply on 1% Blind, low vision Reservation in Combined Medical Services exam

Gujarat HC rejects plea to quash charges against Gynaecologist in Childbirth Death Case

Denying to grant relief to a gynaecologist booked for culpable homicide not amounting to murder- IPC 304, the Gujarat High Court recently refused to entertain his plea seeking quashing of the proceedings.

The gynaecologist, along with others, was booked after a woman died during childbirth at a Bavla-based hospital back in May 2024. In this connection, Bavla police registered an FIR on September 2.

For more details, check out the full story on the link below:

Patient dies during childbirth, Gujarat HC Rejects Plea to Quash Charges Against Gynaecologist

India witnessed rise in chronic disease deaths between 2010-2019 amid global decline: The Lancet

A recent study published in The Lancet reveals a worrying trend: the risk of dying from non-communicable diseases (NCDs) has increased in India, unlike the global decline observed in most countries. NCDs such as heart disease, chronic respiratory illnesses, and cancers pose growing challenges, particularly affecting Indian women over 40 and men over 55. Between 2010 and 2019, the probability of dying from NCDs rose to 48.7% for women and 57.9% for men in India, with heart disease and diabetes being the top causes.

This contrasts sharply with declines seen in 152 countries for women and 147 for men worldwide during the same period. Experts point to lifestyle factors, pollution, urbanization, and insufficient healthcare access as key drivers. The study also highlights data quality issues in India, making accurate assessments difficult. The findings underscore urgent need for stronger public health policies, improved healthcare infrastructure, and better data collection to combat rising NCD deaths and protect vulnerable populations in India.

REFERENCE: Bennett, James E et al.; Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019; The Lancet, Volume 0, Issue 0; doi: 10.1016/S0140-6736(25)01388-1

Powered by WPeMatico

VACANCIES! SR Post At Indira Gandhi ESIC Hospital Delhi Via Walk In Interview, Hurry To View Details

New Delhi: The Indira Gandhi Employees State Insurance Hospital (IG ESI Hospital Jhilmil) has announced vacancies for the Senior Resident posts in different departments in this medical institute. 

ESI is a statutory body constituted under an Act of Parliament (ESI Act, 1948) and works under the administrative control of the Ministry of Labour and Employment, Government of India.

ESIC Vacancy Details:-

Total no of Vacancies: 25

The Vacancies are in the Departments of Anesthesia, Gynaecology, Surgery, Radiology, ICU, and Peadiatric.

The date of walk In Interview is 16th SEPTEMBER 2025.

Venue and Reporting Time: The office of the Medical Superintendent, IG ESI Hospital, Jhilmil, New Delhi- 110095 At 9.00 AM.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=esic+delhi&location=&job_sector=all

What are the Instructions for Eligible Candidates:-

Applicants are advised to reach the office of the Medical Superintendent, IG ESI Hospital, Delhi on the date of walkin- interview i.e. on 16.09.2025 at 9.00 A.M. as per scheduled interview mentioned in the advertisement along with original documents and one set of photocopies (self-attested) as listed on the application form. No candidate will be entertained after 10.30 A.M

The candidates are advised to bring their all Original Certificates with one set of self-attested photocopies of the following documents during verification: –

1. Identity proof [PAN Card, Passport, Driving License, Voter Card, Aadhar Card etc.]

2. Address Proof [Ration Card, Passport, Driving License, Aadhar Card etc.]

3. Certificate showing date of birth [10th certificate/Birth certificate]

4. Two recent passport size photographs

5. Photocopies of Aadhar/PAN Card and Bank Passbook [At the time of joining for only selected candidates]

6. Class 10th/12th mark sheets and certificates

7. MBBS, MD/MS/DNB/DM and Experience certificates whichever is applicable as per NMC guidelines.

8. Registration with Delhi Medical Council.

9. Internship completion certificate.

10. Reservation category certificate [OBC/SC/ST/PH/EWS] in the format prescribed by Govt. of India.

11. NOC certificate from present employer if applicable

12. Experience certificate if applicable.

13. Income and Asset certificate from issuing Authority as per DOPT letter no. 36039/1/2019. Esst. (Res) dated 31st January 2019 must be submitted for the reservation for EWS Category.

Also Read:64 SR Post VACANCIES At ESIC Hospital Faridabad: Check OUT Walk In Interview Details Here….

Powered by WPeMatico

Doctors Urge JnK Govt to Increase Stipend for MBBS Interns

Srinagar: Demanding a stipend hike for the MBBS interns in Jammu and Kashmir, the doctors have urged the Chief Minister, Health Minister, and Director of Health Services of Jammu and Kashmir to intervene. Currently, the MBBS interns in the Union Territory receive Rs 12,000 per month as their stipend.

Highlighting the “urgent need for a significant hike” in the stipend provided to the medical interns in the Union Territory of Jammu and Kashmir, the Democratic Medical Association (DMA) pointed out that “internship is a crucial period in the career of a medical graduate, where they contribute extensively to patient care and public health services under challenging circumstances, often without adequate financial support.”

It pointed out that currently, the J&K medical inerns get insufficient amount of stipend, causing severe financial difficulties and demoralizing young doctors who are serving the healthcare system with dedication.

In its letter, the association mentioned, “It is important to mention here that in the past as well, several efforts and representations have been made regarding this issue, but unfortunately no conclusive action has been taken so far. This prolonged delay has created frustration among young doctors who continue to serve selflessly despite financial constraints.”

Further, the association highlighted how several states across India have already revised the internship stipend in line with the rising cost of living and the contribution of interns. “Unfortunately, the stipend in J&K has not been brought at par, creating disparity and discontent among the young medical workforce,” DMA mentioned in the letter.

“In view of the above, we strongly urge your esteemed office to consider and implement a substantial revision in the internship stipend at the earliest possible time. This step will not only uplift the morale of the young medical workforce but also ensure better healthcare services for the people of Jammu & Kashmir. We remain hopeful that under your leadership, this long-standing demand will be addressed with priority and sensitivity,” it further added.

The letter has been addressed to the Hon’ble Chief Minister Shri Omar Abdullah and Health Minister Smt. Sakeen Masood (Itoo) and it has been jointly drafted and signed by Dr. Amit Vyas (National Chief & National President), Dr. Shubh Pratap Solanki (National General Secretary), Dr. Sheikh Amir (National Faculty), and Dr. Kamal Singh (National Joint Secretary) of DMA.

Commenting on the matter, the National President of DMA, Dr. Amit Vyas said, “We are hopeful that the Hon’ble Chief Minister and Health Minister will take up this long-pending demand with sensitivity and priority.”

Medical Dialogues had earlier reported that recently the Vice President of All India Medical Students Association (AIMSA) , Dr. Mohammad Momin Khan also requested the CM’s intervention to ensure a stipend hike for the MBBS interns in J&K.

Highlighting that the MBBS interns of J&K receive a stipend of only Rs 12,000 per month, Dr. Khan mentioned in a letter addressed to the Chief Minister of J&K, Mr. Omar Abdullah that “Despite repeated assurances over the past six years, no substantial progress has been made, leaving young medical graduates disheartened and financially strained.”

Also Read: JnK CM’s intervention sought for MBBS intern stipend hike

Powered by WPeMatico

AI algorithm turns mammograms into a ‘two-for-one’ test for women’s heart health

An AI algorithm based only on routine mammogram images plus age can predict a woman’s risk of major cardiovascular disease as well as standard risk assessment methods, finds research published online in the journal Heart.

Powered by WPeMatico

Engineered antibodies can direct T-cells to kill cytomegalovirus-infected cells

A UCLA research team has found a new way to prompt the immune system to kill cells infected with cytomegalovirus (CMV), a life-threatening infection that is particularly deadly in immunocompromised people.

Powered by WPeMatico

Developing novel drug for acute MI, acute kidney injury, and subsequent chronic organ failure: Study

Acute myocardial infarction and acute kidney injury are life-threatening conditions caused by ischemia, resulting from reduced or blocked blood flow to organs. Although early restoration of blood flow improves survival, many patients still develop chronic heart or kidney failure. The mechanisms driving this transition from acute tissue injury to chronic dysfunction remain poorly understood, and effective treatments are lacking.

In this study, researchers focused on the immune receptor CD300a, which suppresses immune cell activation. Using a mouse model with genetic deficiency of CD300a, they investigated the progression from AMI and AKI to chronic heart and kidney failure. The findings revealed that CD300a deficiency attenuated cardiac dysfunction caused by AMI and reduced subsequent cardiac fibrosis, thereby preserving cardiac function. Similarly, renal dysfunction following AKI was less severe, renal fibrosis in chronic kidney failure was diminished, and renal function was maintained.

The mechanism underlying these protective effects is as follows: in ischemic heart and kidney tissues, CD300a deficiency enhanced macrophage-mediated phagocytosis of dead cells, reducing inflammation. Moreover, in CD300a-deficient mice, SiglecF-/lo neutrophils exhibited increased production of angiogenic and antifibrotic factors, which inhibited progression to chronic organ failure. Importantly, administration of neutralizing antibodies against CD300a in mice produced outcomes comparable to those observed in CD300a-deficient models, suppressing the progression to chronic heart and kidney failure.

The research group now aims to evaluate the efficacy and safety of humanized anti-human CD300a neutralizing antibodies in clinical studies, with the ultimate goal of developing novel therapeutic agents for acute tissue injury and subsequent chronic organ failure in the heart and kidney.

Reference:

Nanako Nishiyama, Hitoshi Koizumi, Chigusa Nakahashi-Oda, Satoshi Fujiyama, Xuewei Ng,Hanbin Lee, Fumie Abe,CD300a immunoreceptor regulates ischemic tissue damage and adverse remodeling in the mouse heart and kidney, Journal of Clinical Investigation, DOI:10.1172/JCI184984 

Powered by WPeMatico

Using deep learning for precision cancer therapy

Nearly 50 new cancer therapies are approved every year. This is good news. “But for patients and their treating physicians, it is becoming increasingly difficult to keep track and to select the treatment methods from which the people affected—each with their very individual tumor characteristics—will benefit the most,” says Dr. Altuna Akalin, head of the Bioinformatics and Omics Data Science technology platform at the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB).

Powered by WPeMatico

Novel PET tracer detects synaptic changes in spinal cord and brain after spinal cord injury

A new PET tracer can provide insights into how spinal cord injuries affect not only the spinal cord, but also the brain, according to new research published in The Journal of Nuclear Medicine. By identifying synapse loss, the PET approach provides molecularly unique and complementary information to other structural imaging methods, offering a promising objective metric to evaluate novel therapeutics for spinal cord injuries.

Powered by WPeMatico

Ebola vaccine reaches epicenter of Congo outbreak as officials race to contain spread

Limited access and required funding are the key challenges facing health officials trying to respond to the latest Ebola outbreak in southern Congo, the World Health Organization said on Friday.

Powered by WPeMatico

AOPT-LTL Therapy Improves Melasma via SCF/c-KIT Pathway Inhibition: Study Finds

China: A new study has revealed that AOPT-LTL therapy significantly improves melasma by reducing melanogenesis, inflammation, angiogenesis, mast cell infiltration, and collagen degeneration, likely via inhibition of the SCF/c-KIT signaling pathway.

The study, led by Bingrong Zhou and colleagues from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China, was published in the Journal of Cosmetic Dermatology. The research assessed both the effectiveness and the biological mechanisms of advanced optimal pulse technology intense pulsed light in low-energy triple-pulse long-width mode (AOPT-LTL) for treating melasma.
To explore this, the investigators first developed an animal model of melasma using guinea pigs exposed to progesterone injections and ultraviolet B radiation. Animals were then treated with three sessions of AOPT-LTL therapy administered weekly. Alongside this preclinical work, 20 patients with melasma underwent three monthly sessions of the same treatment. Their progress was evaluated using the Modified Melasma Area and Severity Index (mMASI) and the Erythema Index (EI).
The study led to the following findings:
  • In the animal model, AOPT-LTL treatment significantly reduced pigmentation and suppressed genes associated with melanin production.
  • The therapy decreased mast cell infiltration and lowered the expression of inflammatory and angiogenic factors.
  • By inhibiting angiogenesis and reducing collagen breakdown, the treatment improved skin quality and alleviated signs of photoaging.
  • AOPT-LTL also blocked the SCF/c-KIT signaling pathway, which regulates mast cell activity and proliferation, suggesting a key molecular mechanism behind its effects.
  • Clinical results were consistent with the experimental findings, showing clear therapeutic benefits in patients.
  • After three sessions, patients experienced reduced melanin levels and erythema, along with improved mMASI and EI scores.
  • The improvements demonstrated both lightening of pigmentation and reduced redness, supporting its effectiveness in enhancing skin tone and texture in melasma.
The authors emphasized that AOPT-LTL therapy offers multiple benefits beyond pigment reduction, targeting inflammation, angiogenesis, and structural degeneration, which are all key processes involved in melasma pathology. By acting on several pathways simultaneously, it may provide a more comprehensive approach compared to conventional treatment modalities.
However, the researchers also acknowledged certain limitations. The study lacked direct head-to-head comparisons with conventional IPL methods, making it difficult to quantify its relative advantages. The sample size of patients was small, and the follow-up period was short, meaning long-term recurrence rates could not be fully assessed. Further laboratory studies are also required to confirm the precise mechanisms of mast cell inhibition observed in vivo.
“The study demonstrated that AOPT-LTL therapy can effectively treat melasma through its broad-spectrum action on melanogenesis, inflammation, vascular changes, and collagen degradation. With its ability to target multiple biological pathways, it shows promise as a novel therapeutic option for patients with melasma, although larger and longer clinical trials are needed to validate its long-term efficacy and safety,” the authors concluded.
Reference:
Wang, J., Wang, X., Gu, L., Shi, Z., Xu, Z., Shen, S., Gu, L., Chen, L., Ju, L., Jin, C., Zhou, B., & Hua, H. (2025). Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study. Journal of Cosmetic Dermatology, 24(9), e70443. https://doi.org/10.1111/jocd.70443

Powered by WPeMatico